Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Expands By 76.7%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 33,400 shares, an increase of 76.7% from the June 30th total of 18,900 shares. Currently, 4.0% of the shares of the company are sold short. Based on an average daily volume of 278,600 shares, the short-interest ratio is presently 0.1 days.

ZyVersa Therapeutics Stock Performance

NASDAQ ZVSA opened at $3.85 on Friday. ZyVersa Therapeutics has a 1 year low of $3.41 and a 1 year high of $79.80. The company has a fifty day moving average of $4.33 and a 200 day moving average of $6.00.

ZyVersa Therapeutics (NASDAQ:ZVSA) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($4.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.70) by ($0.83). As a group, analysts predict that ZyVersa Therapeutics will post -15.05 EPS for the current year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.